Summary
Introduction
Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.
Scope
- Research and analysis of the MTT pipeline with in-depth clinical and commercial assessment of Phase III candidates
- Seven major pharmaceutical market sales forecasts to 2016 for key pipeline candidates incorporating product specific assumptions and events
- Segmentation and examination of product pipeline by developmental phase, class, mode of action, indication and developer
- Insight and analysis of market potential including commercial opportunity, commonalities across cancers and discussion of unmet needs
Highlights
329 different pipeline candidates have been identified of which 24 are in late-phase development. These identified candidates have a forecast sales potential of up to $6.03 billion in the seven major pharmaceutical markets by 2016.
Among agents with the greatest commercial potential are the angiogenesis inhibitors Recentin (cediranib; AstraZeneca), aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and pazopanib (GlaxoSmithKline).
Other candidates holding particular promise include the only preregistered agent Novartis's Gleevec-follow-on Tasigna (nilotinib), Novartis's mTOR inhibitor Certican (everolimus), and Biogen Idec's anti-CD23 monoclonal antibody, lumiliximab.
Reasons to Purchase
- Acquire a detailed appreciation and impartial perspective of the entire molecular targeted therapies developmental pipeline
- Identify the key products in late-phase development based on sales forecasts to 2016 and Datamonitor's drug assessment methodology
- Assess the shifting oncology market dynamic and how future treatment of many cancers will incorporate pipeline products
|
